Emyria Ltd (ASX:EMD) managing director Michael Winlo speaks with Andrew Scott from Proactive about signing up eight clinical sites across Australia to support a pivotal Phase 3 clinical trial of EMD-RX5. This is the company’s first ultra-pure cannabinoid treatment and the trial is now accessible to participants across Western Australia, Queensland, New South Wales, South Australia and the Australian Capital Territory. Winlo discusses EMD-RX5 and what makes it unique.
Emyria takes EMD-RX5 pivotal trial nationwide
